Investing.com - Cytokinetics Inc (NASDAQ: CYTK) reported second quarter EPS of $-1.34, $0.20 worse than the analyst estimate of $-1.14. Revenue for the quarter came in at $870K...
Cytokinetics (NASDAQ:CYTK) shares rose more than 3% today after JPMorgan raised its price target on the company to $54.00 from $52.00 while maintaining an Overweight. The price...
Investing.com - Cytokinetics Inc (NASDAQ: CYTK) reported first quarter EPS of $-1.38, $0.18 worse than the analyst estimate of $-1.20. Revenue for the quarter came in at $4.61M...
Investing.com - Cytokinetics Inc (NASDAQ: CYTK) reported first quarter EPS of $-1.45, $0.24 worse than the analyst estimate of $-1.21. Revenue for the quarter came in at $1.96M...
Cytokinetics (NASDAQ:CYTK) reported Q4 EPS of ($1.45), $0.24 worse than the analyst estimate of ($1.21). Revenue for the quarter came in at $1.96 million versus the consensus...
Cytokinetics (CYTK) reported Q3 EPS of ($1.52), $0.35 worse than the analyst estimate of ($1.17). Revenue for the quarter came in at $2.52 million versus the consensus estimate of...
Investing.com - Cytokinetics (NASDAQ:CYTK) Inc reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of...